secwatch.observer — SEC 8-K summary
======================================

Issuer:     Abpro Holdings, Inc. (ABPO)
CIK:        0001893219
Form:       8-K
Filed at:   2025-02-21T23:59:59+00:00
Accession:  0001213900-25-016110
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abpro provides pipeline update; Celltrion partnership for ABP-102 fully funded with up to $1.75B milestones
--------------------------------------------------------------------------------

- Celltrion funds all development of ABP-102 (HER2/CD3 T-cell engager) for breast/gastric cancer; Abpro retains 50% profit share.
- ABP-201 (VEGF/ANG2) for Wet AMD/DME: IND filing expected Q1 2026, Phase 1 start same year.
- ABP-102 IND filing targeted for 2H 2025; Phase 1 initiation in 1H 2026.
- Additional pipeline: ABP-150 (Claudin18.2/CD3) and ABP-110 (GPC3/CD3) IND filings in 2026, Phase 1 in 2027.
- No financial results; presentation highlights platform, preclinical data, and upcoming milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025016110/0001213900-25-016110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1893219/000121390025016110/ea0231728-8k_abpro.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-016110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer